Skip to main content
ClinicalTrials.govrestricted

Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy

ClinicalTrials.gov study NCT02448290. IPD Sharing: Not stated. Countries: 1. Publications: 0.

ShareScore

24/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
12
Harmonization
8
Access
0
Reuse readiness
0
Engagement
4

Topics